Orthofix Medical Inc. — Third Quarter 2026 Earnings Summary

Orthofix Medical Inc. reported a net loss of $6.1 million for the third quarter of 2026, with total net sales reaching $207.9 million, representing a 1% increase on a reported basis. The company revised its full-year 2026 net sales guidance down to a range of $825 million to $830 million and adjusted EBITDA guidance to $86 million to $88 million. While Global Limb Reconstruction and Therapeutic Solutions sales grew by 8% and 4% respectively, Spine Fixation sales remained flat, prompting strategic actions to improve U.S. Spine execution and asset productivity. Non-GAAP adjusted EBITDA for the quarter was $26.0 million, reflecting continued cost discipline despite lower Spine revenue and unfavorable geographic mix.